Proliferative diabetic retinopathy: Predictive and preventive measures at hypoxia induced retinal changes

EPMA Journal

Volumn 1, Issue 1, 2010, Pages 73-77

  Josifova, Tatjana ^a   Plestina Borjan, Ivna ^b   Henrich, Paul Bernhard ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL SPLIT   (Croatia)

Author keywords

Individualized treatment algorithms; Innovative molecular imaging technology; Intravitreal drug application; New classification and guidelines; Prediction prevention at initial stages; Proliferative diabetic retinopathy

Indexed keywords

ALPHA INTEGRIN; BASIC FIBROBLAST GROWTH FACTOR; BETA3 INTEGRIN; BEVACIZUMAB; CYSTEINE; HEMOGLOBIN A1C; HYPOXIA INDUCIBLE FACTOR 1; INSULIN; OSTEONECTIN; PIGMENT EPITHELIUM DERIVED FACTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN ROBO4; RANIBIZUMAB; ROSIGLITAZONE; ROUNDABOUT RECEPTOR; SCATTER FACTOR; SOMATOMEDIN C; SOMATOSTATIN; STEROID; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR BETA; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CLINICAL EFFECTIVENESS; COST OF ILLNESS; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EARLY INTERVENTION; HUMAN; HYPOXIA; LASER COAGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PREDICTION; PREVENTION STUDY; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PROTEIN EXPRESSION; RETINA NEOVASCULARIZATION; TREATMENT PLANNING; VITRECTOMY; VITREOUS HEMORRHAGE;

EID: 79953051474     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-010-0003-8     Document Type: Article

References (25)

1. American Academy of Ophthalmology. 2002. http://www.aao.org
2. Adamiec-Mroczek J, Oficjalska-Mlynczak J, Misiuk-Hoilo M. Proliferative diabetic retinopathy-The influence of diabetes control on the activation of the intraocular molecule system. Diabetes Res Clin Pract. 2009;84(1):46-50.
3. Lewis H, Ryan RS. Medical and Surgical Retina. London: Mosby; 1994.
4. Gunduz K, Bakri SJ. Management of proliferative diabetic retinopathy. Compr Ophthal Update. 2007;8(5):245-56.
5. Simo R, Carrasco E, Garcia-Ramirez M, et al. Angiogenic and antiangiogenic factors in proliferitive diabetic retinopathy. Curr Diabetes Rev. 2006;2(1):71-98.
6. Ning A, Cui J, Maberley D, et al. Expression of integrins in human proliferative diabetic retinopathy membranes. Can J Ophthalmol. 2008;43(6):683-8.
7. Praidou A, Klangas I, Papakonstantinou E, et al. Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy. Curr Eye Res. 2009;34(2):152-61.
8. Fujioka S, Karashima K, Saito Y. Differences of ocular circulation in eyes with proliferative diabetic retinopathy after panretinal photocoagulation with and without rubeosis iridis. Nippon Ganka Gakkai Zasshi-Acta Societatis Ophthalmologicea Japonicae. 2009;113(1):11-5.
9. Vernon SA, Bhagey J, Boraik M, et al. Long-term review of driving potential following bilateral panretinal photocoagulation for proliferative diabetic retinopathy. Diabet Med. 2009;26(1): 97-9.
10. Nakamura S, Iwasaki N, Funatsu H, et al. Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2009;247(1):21-6.
11. Watanabe K, Okamoto F, Yokoo T, et al. SPARC is a major secretory gene expressed and involved in the development of proliferative diabetic retinopathy. J Atheroscler Thromb. 2009;16 (2):69-76.
12. Huang L, Yu W, Li X, et al. Expression of Robo4 in the fibrovascular membranes from patients with proliferative diabetic retinopathy and its role in RF/6A and RPE cells. Mol Vis. 2009;15:1057-69.
13. Petrovic MG, Korosec P, Kosnik M, et al. Vitreous levels of interleukin-8 in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2007;143(1):175-6.
14. You JJ, Yang CH, Chen MS, et al. Cysteine-rich 61, a member of the CCN family, as a factor involved in the pathogenesis of proliferative diabetic retinopathy. Investig Ophthalmol Vis Sci. 2009;50(7):3447-55.
15. Shen LQ, Child A, Weber GM, et al. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol. 2008;126(6):793-9.
16. Zhang P, Liu N, Wang Y. Insulin may cause deterioration of proliferative diabetic retinopathy. Med Hypotheses. 2009;72(3):306-8.
17. Mason 3rd JO, Yunker JJ, Vail R, et al. Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathy. Retina. 2008;28(9):1319-24.
18. Moradian S, Ahmadieh H, Malihi M, et al. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2008;246(12):1699-705.
19. Arevalo JF, Wu L, Sanchez JG, et al. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy: 6-months follow-up. Eye. 2009;23(1):117-23. 22.
20. Mason 3rd JO, Nixon PA, White MF. Intravitreal of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142(4):685-8. 23.
21. Oshima Y, Sakaguchi H, Gomi F, et al. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142(1):155-8. 25.
22. Arimura N, Otsuka H, Yamakiri K, et al. Vitreos mediator after intravitreal of bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Ophthalmology. 2009;116 (5):921-6. 25.
23. Thew M. Rapid resolution of severe retinal neovascularization in proliferative diabetic retinopathy. Clin Exp Optom. 2009;92 (1):34-7.
24. Ishikava K, Hinda S, Tsukahara Y, et al. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye. 2009;23(1):108-11.
25. Park SP, Ahn JK, Lee GH. Morphologic changes in the anterior segment after phacovitrectomy for proliferative diabetic retinopathy. J Cataract Refract Surg. 2009;35(5):868-73.